Answers are grounded in this paper and cite their sources.
Background and objective: Patient-reported outcome measures (PROMs) are increasingly being used to evaluate health-related quality of life (HRQoL) in cancer care. We investigated the effects of treatment for both localized (M0) and metastatic renal cell carcinoma (mRCC) on generic and cancer-specific HRQoL up to 15 wk after diagnosis. Methods: were also performed. Key findings and limitations: = 0.017). Conclusions and clinical implications: Patients with M0 disease and mRCC experienced improvements in several functional and symptom domains within 15 wk after diagnosis. Future studies should assess the impact of these changes on treatment continuation and/or responses. Patient summary: We looked at health-related quality of life (HRQoL) in patients with localized or metastatic kidney cancer. In general, both groups reported improvements in emotional, social, and physical wellbeing at 15 weeks after their diagnosis, and results suggest further changes at 6 months after diagnosis. Patients reported improvements in symptoms such as fatigue, pain, sleep, and appetite. Our results indicate that patients can find meaningful improvements in their quality of life shortly after diagnosis and initiation of treatment.
No takes yet. Share an insight, caveat, or question.
Duijn et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: